Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
M&A
Data Integration Drives Successful Mergers
In an M&A transaction, disparate data and disconnected systems require a data integration game plan.
By
Stacy Galligan
| May 16, 2022
Read More
Resources
CFO Live
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
Sign Up
Sponsored by
animal health
IPOs
Lilly’s Elanco Expects IPO to Raise $1.4B
The animal health spinoff is the second major industry player to go public, following Zoetis' successful offering.
By
Matthew Heller
| September 6, 2018
Read More
Corporate Finance
Eli Lilly to Spin Off Animal-Health Business
Eli Lilly reported a quarterly loss of $260 million and announced plans for an IPO of Elanco by the end of 2018.
By
William Sprouse
| July 24, 2018
Read More
Strategy
Lilly Buys Vetmedica Pet Vaccines for $885M
The deal will diversify Lilly's Elanco animal medicine business, adding vaccines for rabies and other feline and canine illnesses.
By
Matthew Heller
| October 5, 2016
Read More
Strategy
Zoetis Gives Back Post-Takeover Report Gains
Shares in the animal-health giant take a rollercoaster ride after a report of a possible acquisition by Valeant Pharmaceuticals.
By
Matthew Heller
| June 26, 2015
Read More